HRB Open Res 2020 10;3. Epub 2020 Feb 10.
Department of General Practice and HRB Centre for Primary Care Research, Royal College of Surgeons in Ireland, Dublin 2, Ireland.
Sacubitril/valsartan is a first-in-class angiotensin-receptor neprilysin inhibitor used to treat heart failure with reduced ejection fraction. The evidence base for this novel medication is largely based on one pivotal phase III trial which was stopped early due to significant clinical benefits being shown. However potential limitations in the trial design have been highlighted in recent medical literature, necessitating a thorough review of the evidence base for sacubitril/valsartan. Read More